Research on the Use of Probiotics in the Prevention and Treatment of Inflammatory Bowel Disease

This study evaluates oral Lactobacillus reuteri as an adjunct therapy for 2 months. Endoscopic assessments will be performed at baseline and after 2 months of intervention to evaluate intestinal inflammation. Intestinal fluid samples will be collected during endoscopy for 16S rRNA gene sequencing to assess changes in the gut microbiota. Peripheral blood inflammatory markers and fecal calprotectin levels will also be measured to evaluate changes in intestinal inflammation.

Inclusion Criteria: 1. Be over 18 years old 2. Agree to sign informed consent; Have been diagnosed with IBD for at least 3 months but not more than 3 years - Exclusion Criteria: 1. Does not meet the diagnostic criteria of CD 2. Patients with other autoimmune diseases, infectious diseases and malignant tumors Patients with CD during pregnancy and lactation; Patients with serious diseases of the liver, kidney, heart and lung, etc 3. Patients with allergic diseases such as asthma and allergic rhinitis; alcoholic Patients with mental illness 4. Patients with suspected cancer in their intestines 5. Antibiotics, probiotics and prebiotics have been used in the past three months Had intestinal surgery (except appendicitis surgery) 6. There is currently an infection 7. He has had cancer in the last 5 years -